Vascular Bubble Generation for Diagnosis and Therapy

描述(由申请人提供)：提出了经皮声雾化血管栓塞术(ADV)的发展和大型动物试验。在静脉注射、输液后，在体温下过热的液滴将通过通过皮肤施加超声波，在体内所需位置蒸发成微泡。这将允许在目标部位进行快速、微创的血管闭塞。预计这种治疗将比在紧急情况下或在热、空化或手术干预之前减少血流或出血的同类血管造影技术更快、更便宜、更具侵入性，并可能被证明是一种比热或手术干预更快、更便宜、更具侵入性的完整局部治疗。研究了必要的液滴生成和汽化过程。来自ADV的30-120微米的气泡已被证明对处理体积或可识别的供应血管中的浅表麻风和犬组织区域的梗塞具有适当的性质。犬肾脏的治疗研究在原位ADV的权威测试中得到了解决。具体地说，建议从以前证明的动脉内注射液滴的气泡闭塞过渡到静脉注射液滴乳剂的气泡闭塞。在从经肺小滴产生必要的气泡浓度后，通过经皮在非浅供血动脉，例如节段肾动脉，然后是整个肾动脉，在被膜动脉或被囊动脉本身分支之前，通过经皮汽化这些小液滴，将产生类似的大量气泡。深度ADV将通过使用治疗阵列来实现，该治疗阵列具有适当的射束形状用于全动脉栓塞术，并且对于深度ADV具有超过足够的焦点增益、功率和压力幅度。在组织死亡所需的时间内完全栓塞肾皮质组织，甚至是准备和执行其他程序的时间，如部分肾切除、射频或冷冻消融术，将是节省时间以及这些替代或后续肾脏消融/切除程序的并发症和死亡率的宝贵工具。然后，将在犬肾脏中使用性病肉瘤癌症模型，以验证ADV为直接或结合射频消融治疗癌症提供栓塞治疗的能力。ADV只需要静脉注射液滴和经皮超声波。类似的人体试验应该准备好在下一次更新中实施。

DESCRIPTION (provided by applicant): Developments and large animal trials of vascular embolization by transcutaneous Acoustic Droplet Vaporization (ADV) are proposed. After, intravenous, infusion, superheated droplets at body temperature will be caused to vaporize into microbubbles at the desired location in the body by applying ultrasound through the skin. This will allow rapid, minimally invasive vascular occlusion at targeted sites. It is expected that this treatment will be faster and less expensive and invasive than comparable angiographic techniques for reducing flow or hemorrhage in emergency situations or before thermal, cavitational or surgical interventions and may prove much faster and less expensive and invasive as a complete local treatment than either thermal or surgical intervention. Necessary droplet production and vaporization processes have been studied. The 30- 120 um bubbles from ADV have been shown to have suitable properties for infarction of superficial leporine and canine tissue regions in either the treated volume or identifiable supply vessels. Therapeutic studies in the canine kidney are addressed in definitive tests of in situ ADV. Specifically, it is proposed to transition from previously demonstrated occlusion by bubbles from intra-arterial droplet injections to occlusion by bubbles from intravenous injections of droplet emulsions. After achieving the generation of necessary bubble concentrations from transpulmonary droplets, similar copious quantities will be produced by transcutaneous vaporization of these droplets in non-superficial feeder arteries, e.g., a segmental renal artery and then the entire renal artery prior to branching of the capsular arteries or the capsular arteries themselves. ADV at depth will be achieved by use of a therapeutic array with appropriate beam shape for full arterial embolization and more than adequate focal gain, power and pressure amplitude for deep ADV. Full embolization of renal cortical tissue for the time required for tissue death, or even the time to prepare and perform other procedures such as partial nephrectomy or RF or cryo-ablation, will be an invaluable tool for saving time, as well as complications and mortality in those alternative or subsequent kidney ablation/resection procedures. The venereal sarcoma cancer model will then be employed in the canine kidney to verify the ability of ADV to provide embolization therapy for treating cancer directly, or in combination with RF ablation. The ADV only requires an intravenous injection of droplets and transcutaneous ultrasound. Similar human trials should be ready for implementation in the next renewal.